• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Pembrolizumab plus chemotherapy improved survival in a subgroup of triple-negative metastatic breast cancer

byJohan PushaniandSze Wah Samuel Chan
December 28, 2022
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Pembrolizumab plus chemotherapy for triple-negative breast cancer significantly increased PFS and OS among patients whose tumours expressed PD-L1 with a CPS of 10 or more.

2. Occurrence of adverse events of grades 3 or higher was similar among in both arms, with the most common ones being anemia, neutropenia, and fatigue.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In a previous interim analysis, pembrolizumab (a programmed cell death 1 inhibitor) plus chemotherapy in metastatic triple-negative breast cancer had shown an increased progression-free survival (PFS) in patients with a PD-L1 combined positive score (CPS) of 10 or more [CPS was defined as the number of PD-L1 staining cells]. In its final analysis, this study then explored overall survival (OS). Patients were randomly assigned to receive pembrolizumab plus the physicians’ choice of chemotherapy or placebo and chemotherapy. Primary end points for this final analysis were OS among patients with a CPS score of 10 or more, OS among patients with a CPS score of 1 or more, and OS in the intention-to-treat population. In the CPS-10 subgroup, median OS was significantly longer in the combination arm, whereas in the CPS-1 subgroup, there was no significant difference in median OS between arms. The OS in the intention-to-treat population was similar in both arms. Objective response rate (ORR) was higher in the combination arm of each subgroup, with the largest difference between arms in the CPS-10 subgroup. Duration of response was also highest in this subgroup. Incidence of adverse events of grades 3 or higher occurred similarly in both arms. Most common adverse events of grades 3 or higher were anemia, neutropenia, and fatigue across both arms. Common immune-related events included endocrinopathies such as hypothyroidism with no new safety signals. Limitations to this study include variability in each physician’s choice of chemotherapy such as nab-paclitaxel vs. paclitaxel. Overall, addition of pembrolizumab to chemotherapy strengthens the evidence for this FDA-approved option as a viable treatment option for triple-negative breast cancer patients whose tumours expressed PD-L1 with a CPS of 10 or more.

Click to read the study in NEJM

Relevant Reading: Triple-negative breast cancer: adjuvant therapeutic options

RELATED REPORTS

Structured exercise intervention improves survival in colon cancer patients

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

In-Depth [randomized control trial]: This international phase III trial included a total of 847 patients with triple-negative breast cancer whose tumours expressed PD-L1 and a CPS, who were randomly assigned in a 2:1 ratio to receive pembrolizumab plus chemotherapy or placebo plus chemotherapy; 566 were in the combination arm and 281 in the chemotherapy arm. In the CPS-10 subgroup, median OS was 23.0 months and 16.1 months for the combination and chemotherapy arms, respectively (hazard ratio for death [HR], 0.73; 95% confidence interval [CI], 0.55 to 0.95; P=0.0185). In the CPS-1 subgroup, median OS was 17.6 months vs. 16.0 months (HR, 0.86; 95% CI, 0.72 to 1.04; P=0.1125. In the intention-to-treat population, the median OS was 17.2 months vs. 15.5 months (HR, 0.89; 95% CI, 0.76 to 1.05, [significance not tested]). In the CPS-10 subgroup, ORR was 52.7% for the combination arm and 40.8% for the chemotherapy arm. Adverse events of grades 3 or higher occurred in 68.1% of patients in the combination arm and in 66.9% of patients in the chemotherapy arm. Most common adverse events of grades 3 or higher were anemia (16.5% in combination group vs. 14.6% in chemotherapy group), neutropenia (29.7% vs. 29.9%), and fatigue (2.8% vs. 2.5%). Immune-related adverse events most commonly included thyroid dysfunction. Overall, the addition of pembrolizumab to chemotherapy for triple-negative breast cancer significantly increased PFS and OS among patients whose tumours expressed PD-L1 with a CPS of 10 or more.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Alcohol recovery narratives are dynamic and may be composed of multiple dimensions

Next Post

Patterns of anti-VEGF treatment for retinopathy of prematurity vary by country

RelatedReports

Development of a risk index for colorectal cancer screening
Gastroenterology

Structured exercise intervention improves survival in colon cancer patients

July 9, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025
Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation
Cardiology

Cerebral embolic protection does not decrease stroke incidence in TAVI patients

July 8, 2025
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Pharma

Nerandomilast slows FVC decline in progressive pulmonary fibrosis

July 8, 2025
Next Post
Head circumference better predicts labor dystocia than weight

Patterns of anti-VEGF treatment for retinopathy of prematurity vary by country

AAP recommends disaster preparedness measures for children

The Pfizer-BioNTech vaccine confers moderate protection against COVID-19 in children

Separate panels of microRNAs may aid in early detection of pancreatic cancer

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.